非转移性肌层浸润性膀胱癌的治疗:AUA/ASCO/SUO指南(2017年;2020年、2024年修订)
该指南由AUA联合ASCO与SUO制定,2024年修订纳入2020年5月至2023年11月的文献,共筛选3739篇摘要,46篇符合纳入标准。更新涉及新辅助/辅助化疗、根治性膀胱切除术、盆腔淋巴结清扫、多模式保膀胱治疗及未来方向,旨在为肌层浸润性尿路上皮癌提供风险分层的临床管理框架。
要点
- 指南提供肌层浸润性膀胱癌风险分层的临床管理框架。
- 2024年修订纳入2020年5月至2023年11月文献,46篇符合纳入标准。
- 更新涉及新辅助/辅助化疗、根治性膀胱切除术、盆腔淋巴结清扫、多模式保膀胱治疗及未来方向。
核心结论
- 该指南旨在基于现有证据提高临床医生对肌层浸润性膀胱癌患者的评估和治疗能力,未来研究对进一步支持或完善这些陈述以改善患者照护至关重要。
研究设计与样本
- 该指南为AUA/ASCO/SUO制定的肌层浸润性膀胱癌指南,2024年通过AUA修订流程更新,检索2020年5月至2023年11月文献,筛选3739篇摘要,46篇符合纳入标准。
主要发现
- 更新涉及新辅助/辅助化疗、根治性膀胱切除术、盆腔淋巴结清扫、多模式保膀胱治疗及未来方向。
- 证据强度分为A(高)、B(中)、C(低),分别支持强推荐、中等推荐或有条件推荐;证据不足时提供临床原则和专家意见。
临床怎么用
- 该指南提供风险分层的临床框架,供临床医生评估和治疗肌层浸润性尿路上皮膀胱癌患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although representing approximately 25% of patients diagnosed with bladder cancer, muscle-invasive bladder cancer (MIBC) carries a significant risk of death that has not significantly changed in decades. Increasingly, clinicians and patients recognize the importance of multidisciplinary collaborative efforts that take into account survival and quality of life concerns. This guideline provides a risk-stratified, clinical framework for the management of muscle-invasive urothelial bladder cancer. METHODOLOGY/METHODS: In 2024, the MIBC guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published guidelines in an effort to maintain currency. The amendment allowed for the incorporation of additional literature released since the previous 2020 amendment. The updated search gathered literature from May 2020 to November 2023. This review identified 3739 abstracts, of which 46 met inclusion criteria.When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions. RESULTS: Updates were made regarding neoadjuvant/adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomy, multi-modal bladder preserving therapy, and future directions. Further revisions were made to the methodology and reference sections as appropriate. CONCLUSIONS: This guideline seeks to improve clinicians' ability to evaluate and treat patients with MIBC based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.
引用
- Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024. PMID: 38661067. doi:10.1097/JU.0000000000003981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。